Literature DB >> 16603214

Bioactivation, protein haptenation, and toxicity of sulfamethoxazole and dapsone in normal human dermal fibroblasts.

Payal Bhaiya1, Sanjoy Roychowdhury, Piyush M Vyas, Mark A Doll, David W Hein, Craig K Svensson.   

Abstract

Cutaneous drug reactions (CDRs) associated with sulfonamides are believed to be mediated through the formation of reactive metabolites that result in cellular toxicity and protein haptenation. We evaluated the bioactivation and toxicity of sulfamethoxazole (SMX) and dapsone (DDS) in normal human dermal fibroblasts (NHDF). Incubation of cells with DDS or its metabolite (D-NOH) resulted in protein haptenation readily detected by confocal microscopy and ELISA. While the metabolite of SMX (S-NOH) haptenated intracellular proteins, adducts were not evident in incubations with SMX. Cells expressed abundant N-acetyltransferase-1 (NAT1) mRNA and activity, but little NAT2 mRNA or activity. Neither NAT1 nor NAT2 protein was detected. Incubation of NHDF with S-NOH or D-NOH increased reactive oxygen species formation and reduced glutathione content. NHDF were less susceptible to the cytotoxic effect of S-NOH and D-NOH than are keratinocytes. Our studies provide the novel observation that NHDF are able to acetylate both arylamine compounds and bioactivate the sulfone DDS, giving rise to haptenated proteins. The reactive metabolites of SMX and DDS also provoke oxidative stress in these cells in a time- and concentration-dependent fashion. Further work is needed to determine the role of the observed toxicity in mediating CDRs observed with these agents.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16603214      PMCID: PMC1615915          DOI: 10.1016/j.taap.2006.02.006

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  55 in total

Review 1.  Role of drug disposition in drug hypersensitivity: a chemical, molecular, and clinical perspective.

Authors:  B K Park; M Pirmohamed; N R Kitteringham
Journal:  Chem Res Toxicol       Date:  1998-09       Impact factor: 3.739

Review 2.  Adverse reactions to sulphonamide and sulphonamide-trimethoprim antimicrobials: clinical syndromes and pathogenesis.

Authors:  A E Cribb; B L Lee; L A Trepanier; S P Spielberg
Journal:  Adverse Drug React Toxicol Rev       Date:  1996-03

3.  Immunochemical detection of arylamine N-acetyltransferase in normal and neoplastic bladder.

Authors:  L A Stanley; E Coroneos; R Cuff; D Hickman; A Ward; E Sim
Journal:  J Histochem Cytochem       Date:  1996-09       Impact factor: 2.479

4.  Covalent binding of sulfamethoxazole reactive metabolites to human and rat liver subcellular fractions assessed by immunochemical detection.

Authors:  A E Cribb; C E Nuss; D W Alberts; D B Lamphere; D M Grant; S J Grossman; S P Spielberg
Journal:  Chem Res Toxicol       Date:  1996-03       Impact factor: 3.739

5.  Metabolism of dapsone to its hydroxylamine by CYP2E1 in vitro and in vivo.

Authors:  A K Mitra; K E Thummel; T F Kalhorn; E D Kharasch; J D Unadkat; J T Slattery
Journal:  Clin Pharmacol Ther       Date:  1995-11       Impact factor: 6.875

6.  Expression of CYP1B1 but not CYP1A1 by primary cultured human mammary stromal fibroblasts constitutively and in response to dioxin exposure: role of the Ah receptor.

Authors:  S E Eltom; M C Larsen; C R Jefcoate
Journal:  Carcinogenesis       Date:  1998-08       Impact factor: 4.944

7.  Dapsone acetylation by human liver arylamine N-acetyltransferases and interaction with antiopportunistic infection drugs.

Authors:  J R Palamanda; D Hickman; A Ward; E Sim; M Romkes-Sparks; J D Unadkat
Journal:  Drug Metab Dispos       Date:  1995-04       Impact factor: 3.922

8.  Formation and elimination of sulphamethoxazole hydroxylamine after oral administration of sulphamethoxazole.

Authors:  A J van der Ven; M A Mantel; T B Vree; P P Koopmans; J W van der Meer
Journal:  Br J Clin Pharmacol       Date:  1994-08       Impact factor: 4.335

9.  Urinary recovery and kinetics of sulphamethoxazole and its metabolites in HIV-seropositive patients and healthy volunteers after a single oral dose of sulphamethoxazole.

Authors:  A J van der Ven; T B Vree; E W van Ewijk-Beneken Kolmer; P P Koopmans; J W van der Meer
Journal:  Br J Clin Pharmacol       Date:  1995-06       Impact factor: 4.335

10.  N4-hydroxylation of sulfamethoxazole by cytochrome P450 of the cytochrome P4502C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic microsomes.

Authors:  A E Cribb; S P Spielberg; G P Griffin
Journal:  Drug Metab Dispos       Date:  1995-03       Impact factor: 3.922

View more
  10 in total

1.  DDS, 4,4'-diaminodiphenylsulfone, extends organismic lifespan.

Authors:  Sung Chun Cho; Moon Cheol Park; Bhumsuk Keam; Jung Min Choi; Yunje Cho; Soonsil Hyun; Sang Chul Park; Junho Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-25       Impact factor: 11.205

Review 2.  Xenobiotica-metabolizing enzymes in the skin of rat, mouse, pig, guinea pig, man, and in human skin models.

Authors:  F Oesch; E Fabian; Robert Landsiedel
Journal:  Arch Toxicol       Date:  2018-06-18       Impact factor: 5.153

3.  Protective effect of 4,4'-diaminodiphenylsulfone against paraquat-induced mouse lung injury.

Authors:  Sung Chun Cho; Ji Heon Rhim; Hae Ri Choi; Young Hoon Son; Seok Jin Lee; Kye Yong Song; Sang Chul Park
Journal:  Exp Mol Med       Date:  2011-09-30       Impact factor: 8.718

4.  Drug antigenicity, immunogenicity, and costimulatory signaling: evidence for formation of a functional antigen through immune cell metabolism.

Authors:  Ayman Elsheikh; Sidonie N Lavergne; J Luis Castrejon; John Farrell; Haiyi Wang; Jean Sathish; Werner J Pichler; B Kevin Park; Dean J Naisbitt
Journal:  J Immunol       Date:  2010-10-27       Impact factor: 5.422

Review 5.  Xenobiotic-metabolizing enzymes in the skin of rat, mouse, pig, guinea pig, man, and in human skin models.

Authors:  F Oesch; E Fabian; K Guth; R Landsiedel
Journal:  Arch Toxicol       Date:  2014-11-05       Impact factor: 5.153

6.  Investigations on detoxification mechanisms of novel para-phenylenediamine analogues through N-acetyltransferase 1 (NAT-1).

Authors:  Gopalakrishnan Venkatesan; Zhi Chiaw Lim; Aneesh V Karkhanis; Yub Raj Neupane; Yuri Dancik; Chenyuan Huang; Paul Bigliardi; Giorgia Pastorin
Journal:  Arch Toxicol       Date:  2021-11-12       Impact factor: 5.153

7.  Inflammatory cytokines suppress arylamine N-acetyltransferase 1 in cholangiocarcinoma cells.

Authors:  Benjaporn Buranrat; Auemduan Prawan; Banchob Sripa; Veerapol Kukongviriyapan
Journal:  World J Gastroenterol       Date:  2007-12-14       Impact factor: 5.742

8.  Acetylation of putative arylamine and alkylaniline carcinogens in immortalized human fibroblasts transfected with rapid and slow acetylator N-acetyltransferase 2 haplotypes.

Authors:  Carmine S Leggett; Mark A Doll; J Christopher States; David W Hein
Journal:  Arch Toxicol       Date:  2020-11-02       Impact factor: 5.153

9.  GWAS identifies an NAT2 acetylator status tag single nucleotide polymorphism to be a major locus for skin fluorescence.

Authors:  Karen M Eny; Helen L Lutgers; John Maynard; Barbara E K Klein; Kristine E Lee; Gil Atzmon; Vincent M Monnier; Jana V van Vliet-Ostaptchouk; Reindert Graaff; Pim van der Harst; Harold Snieder; Melanie M van der Klauw; David R Sell; S Mohsen Hosseini; Patricia A Cleary; Barbara H Braffett; Trevor J Orchard; Timothy J Lyons; Kerri Howard; Ronald Klein; Jill P Crandall; Nir Barzilai; Sofiya Milman; Danny Ben-Avraham; Bruce H R Wolffenbuttel; Andrew D Paterson
Journal:  Diabetologia       Date:  2014-06-17       Impact factor: 10.122

10.  Detoxifying Enzymes at the Cross-Roads of Inflammation, Oxidative Stress, and Drug Hypersensitivity: Role of Glutathione Transferase P1-1 and Aldose Reductase.

Authors:  Francisco J Sánchez-Gómez; Beatriz Díez-Dacal; Elena García-Martín; José A G Agúndez; María A Pajares; Dolores Pérez-Sala
Journal:  Front Pharmacol       Date:  2016-08-04       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.